Image via Wikipedia
SAN DIEGO – Novocell, a small, privately held San Diego company, may have found new ways to make money from its technique for coaxing human embryonic stem cells into insulin-producing pancreatic cells.
That’s good news in a field that has had trouble attracting investor funding. Many venture capital firms have been skittish because of politics and the nascency of the embryonic stem cell science.
The biotechnology company announced Tuesday that it received a patent that essentially gives it control over all endoderm cells made from human embryonic stem cells.
Endoderm cells are precursor cells that can eventually develop into cells
Scientists at the UCSF-affiliated Gladstone Institutes and an international team of researchers have generated a human model of Huntington’s disease — directly from the skin cells of patients with the disease.
For years, scientists have studied Huntington’s disease primarily in post-mortem brain tissue or laboratory animals modified to mimic the disease. Today, in Cell Stem Cell, the international team shows how they developed a human model of Huntington’s disease, which causes a diverse range of neurological impairments. The new model should help scientists better understand the development of Huntington’s — and provide better ways to identify and screen potential therapeutics
Image via Wikipedia
“They call it the ‘global gag rule’ because it forbids federal funding to every international group of family planning which even simply speak about abortion as theoretical possibility.
Officially known as “mexico City Policy”, it has been inserted by Ronald Reagan in 1984 (do you remembe the novel?). Bill Clinton did cancel it on 1993, then George W. Bush made it re-born in 2001, and new President Barack Obama cancelled it again by an executive order.
From now on the United States Agency for International Development (USAID) could restore on its list of payees all the world wide organizations
What are mesenchymal stem cells? where are they found in the human body? What are their most promising clinical applications? Gordana Vunjak-Novakovic of Columbia University gives us an answer to these questions and and an outlook on the future of mesenchymal stem cells.
Medistem Inc. announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The clinical trial uses the company’s “Universal Donor” Endometrial Regenerative Cells (ERC) to treat Congestive Heart Failure (CHF).
According to the study design, after 5 patients enter the trial, they must be observed for a two month time period before additional patients are allowed to enter the study. Patient data was analyzed by the study’s independent Data Safety Monitoring Board (DSMB), which concluded that based on lack of adverse effects,